

Gregory J Riggins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4568191/publications.pdf>

Version: 2024-02-01

44
papers

14,058
citations

279798

23
h-index

276875

41
g-index

45
all docs

45
docs citations

45
times ranked

17591
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of a DNA demethylating agent in combination with <i>all-trans</i> retinoic acid for <i>IDH1</i> -mutant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 711-723.	1.2	5
2	Neutrophil depletion enhanced the <i>Clostridium novyi</i> -NT therapy in mouse and rabbit tumor models. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab184.	0.7	3
3	Post-9/11 excess risk of thyroid cancer: Surveillance or exposure?. <i>American Journal of Industrial Medicine</i> , 2021, 64, 881-884.	2.1	6
4	Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer. <i>Oncotarget</i> , 2021, 12, 1326-1338.	1.8	18
5	The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa149.	0.7	21
6	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.7	13
7	Preventative Effect of Mebendazole against Malignancies in Neurofibromatosis 1. <i>Genes</i> , 2020, 11, 762.	2.4	2
8	Matrix protease production, epithelial-to-mesenchymal transition marker expression and invasion of glioblastoma cells in response to osmotic or hydrostatic pressure. <i>Scientific Reports</i> , 2020, 10, 2634.	3.3	15
9	A role for caveola-forming proteins caveolin-1 and CAVIN1 in the pro-invasive response of glioblastoma to osmotic and hydrostatic pressure. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3724-3738.	3.6	9
10	Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy. <i>SLAS Technology</i> , 2019, 24, 28-40.	1.9	14
11	Feasibility of using NF1-CRD and AAV for gene replacement therapy in NF1-associated tumors. <i>Gene Therapy</i> , 2019, 26, 277-286.	4.5	21
12	Molecular Study of Thyroid Cancer in World Trade Center Responders. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1600.	2.6	9
13	Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1. <i>Journal of Neuro-Oncology</i> , 2019, 143, 207-220.	2.9	8
14	G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. <i>Nature Communications</i> , 2019, 10, 943.	12.8	132
15	Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. <i>Neuro-Oncology</i> , 2019, 21, 189-200.	1.2	49
16	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. <i>Nature Communications</i> , 2018, 9, 1057.	12.8	66
17	CADD-27. G-QUADRUPLEX DNA DRIVES GENOMIC INSTABILITY AND REPRESENTS A TARGETABLE MOLECULAR ABNORMALITY IN ATRX-DEFICIENT MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi280-vi280.	1.2	0
18	EXTH-34. G-QUADRUPLEX DNA DRIVES GENOMIC INSTABILITY AND REPRESENTS A TARGETABLE MOLECULAR ABNORMALITY IN ATRX-DEFICIENT MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi92-vi92.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 529-538.	2.9	34
20	Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. <i>Nature</i> , 2018, 564, 273-277.	27.8	193
21	Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma. <i>ACS Chemical Biology</i> , 2018, 13, 3206-3216.	3.4	27
22	Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks. <i>Oncotarget</i> , 2017, 8, 25955-25962.	1.8	11
23	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0150271.	2.5	21
24	Somatic retrotransposition is infrequent in glioblastomas. <i>Mobile DNA</i> , 2016, 7, 22.	3.6	17
25	Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model. <i>Oncotarget</i> , 2016, 7, 68571-68584.	1.8	56
26	Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. <i>Neuro-Oncology</i> , 2015, 17, 545-554.	1.2	78
27	Repurposing the Anthelmintic Mebendazole as a Hedgehog Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 3-13.	4.1	78
28	Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. <i>Clinical Cancer Research</i> , 2015, 21, 3462-3470.	7.0	66
29	The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. <i>Toxicology in Vitro</i> , 2015, 29, 2038-2044.	2.4	44
30	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. <i>Journal of Neuro-Oncology</i> , 2015, 121, 479-487.	2.9	14
31	<i>Clostridium novyi</i> -NT can cause regression of orthotopically implanted glioblastomas in rats. <i>Oncotarget</i> , 2015, 6, 5536-5546.	1.8	65
32	ET-08 * DEMETHYLATING THERAPY INDUCES DIFFERENTIATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v80-v80.	1.2	0
33	Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses. <i>Science Translational Medicine</i> , 2014, 6, 249ra111.	12.4	285
34	EFFECT OF THE ANTIPARASITIC DRUG MEBENDAZOLE ON CHOLANGIOCARCINOMA GROWTH. <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2014, 45, 1264-70.	1.0	10
35	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. <i>Oncotarget</i> , 2013, 4, 1737-1747.	1.8	141
36	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. <i>Oncotarget</i> , 2013, 4, 1729-1736.	1.8	213

#	ARTICLE	IF	CITATIONS
37	Caveolin-1, caveolae, and glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 679-688.	1.2	48
38	Yes-Associated Protein 1 Is Activated and Functions as an Oncogene in Meningiomas. <i>Molecular Cancer Research</i> , 2012, 10, 904-913.	3.4	57
39	Molecular targeting of glioblastoma: Drug discovery and therapies. <i>Trends in Molecular Medicine</i> , 2011, 17, 301-312.	6.7	114
40	Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. <i>Neuro-Oncology</i> , 2011, 13, 974-982.	1.2	154
41	Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. <i>Neuro-Oncology</i> , 2010, 12, 655-663.	1.2	26
42	<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas. <i>New England Journal of Medicine</i> , 2009, 360, 765-773.	27.0	5,285
43	An Integrated Genomic Analysis of Human Glioblastoma Multiforme. <i>Science</i> , 2008, 321, 1807-1812.	12.6	5,230
44	Mutations of mitotic checkpoint genes in human cancers. <i>Nature</i> , 1998, 392, 300-303.	27.8	1,400